Patents

Epi-C offers standardised and custom epigenetic assays for
HDAC1, HDAC4, HDAC6, SIRT1, P300 and JMJ.

ISIDE

ISIDE 11, a novel SirT1 activator for treatment & prevention of Cardiovascular function/diseases (WO 2020/245468 A1)

APL EPI-METHOD

Method for the prognosis and/or treatment of acute promyelocytic leukemia (Patent:WO2017/1988 A1)

SCIC

Scic compounds, new SIRT1 activators for cardiovascular and metabolic disease (WO2021/018965 A1)

I-SENSOR

I-Sensor immune sensor for mobile detection of polluting substances (PCT 17 727 137.6)

ISIDE 11 is a new compound for prevention of genetic-based MTHFR-C677T mutation in CVD combined with a cardioprotective rule mediated by SIRT1 activation.

No cytotoxic effect
Reduction endothelial dysfunction
Reduction of thrombogenic trait in MTHFR +/- mutation cases

The present invention relates to a method for the diagnostic of low overall survival acute promyelocytic leukemia and/or of predicting and/or monitoring the response and/or the efficacy of a therapy for acute promyelocytic leukemia or to identify a subject to be treated with an inhibitor of HAT and/or an inhibitor of EZH2 comprising determining the acetylation or methylation status of specific relevant regions and relative kit and microarray. The invention also refers to histone acetyl transferase (HAT) inhibitor for use in the treatment of a solid or liquid tumor.

Fig 1: Schematic depiction of the experimental setup and analysis workflow fo APLs.

The present invention refers to useful SIC2 and SCIC2.1, new compounds as SIRT1 activators, in the prevention and/or treatment of cardiovascular and metabolic disease.